Arch Pharmalabs (Arch) has entered into a strategic partnership with Orochem Technologies (Orochem) to manufacture a US innovator’s active pharmaceutical ingredient (API) in late-stage clinical development, using Simulated Moving Bed (SMB) technology. Financial terms of the deal were not disclosed.
Reportedly, the collaboration between Orochem and Arch marks the first time that plant-scale SMB has been used to manufacture an API in India.
Ajit Kamath, CMD at Arch, said: “We are proud to synergise our API development and manufacturing capabilities with SMB technology to work on a US innovator’s molecule in India. Using our flexible SMB capabilities, we can rapidly and cost-effectively tackle separation and purification challenges during scale-up, and provide a reliable API or drug intermediate supply chain throughout the product lifecycle.”
Asha Oroskar, president and CEO at Orochem, said: “By partnering with Arch, we are better able to bring Orochem’s novel products to help pharmaceutical companies achieve higher efficiencies in manufacturing processes requiring separation or purification. This collaboration will significantly benefit our customers by offering dependable and cost-effective solutions during API production.”
Orochem Technologies manufactures SMB equipment and stationary chromatography phases for Bioanalytical, Solid Phase Extraction, Flash and Preparative applications.
Arch Pharmalabs is a provider of API development and manufacturing services to the global pharmaceutical industry. The company’s manufacturing capabilities include bio-catalysis, high-potency manufacturing, cryogenics, phosgenation, organometallics, diketene and other specialized chemistry.